Take Rhopressa® at
the same time each night

This helps you remember
to take your medication and
simplify your
treatment routine.

About Rhopressa®

Rhopressa® is the first FDA-approved medication in its class to lower elevated eye pressure and may help prevent further vision loss in patients with open-angle glaucoma and ocular hypertension.

Consistent eye pressure lowering

Simple dosing routine

Majority of ocular side effects were mild

What to expect with Rhopressa®

How does Rhopressa® work?

When you have open-angle glaucoma or ocular hypertension, the nerve in your eyes is more susceptible to elevated intraocular pressure (IOP). This pressure, if left untreated, can damage the nerve and may lead to progressive and permanent loss of vision.

Rhopressa® is a prescription eye medication that lowers elevated eye pressure by suppressing the "rho kinase" (ROCK) enzymes responsible for the buildup of fluid and the increase in IOP. This improves the drainage of fluid within the inner eye, which reduces pressure.

Possible side effects

The majority of Rhopressa® side effects are mild. Some side effects may go away without stopping the medication, while others like eye redness go away after stopping treatment. The most common side effect of Rhopressa® was eye redness.

Other common side effects include corneal deposits (verticillate), mild pain upon instillation, and a red spot on the white of the eye. These are not all of the possible side effects of Rhopressa®.

For more information, refer to the full Prescribing Information. You are encouraged to report side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

Ask your doctor if Rhopressa® is right for you

Get answers to common questions about Rhopressa® and learn what to ask your doctor at your next eye appointment.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Bacterial Keratitis: Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.

Contact Lenses: Contact lenses should be removed prior to using Rhopressa® and may be reinserted 15 minutes following its administration.

ADVERSE REACTIONS

The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was red eyes, in 53% of patients. Six percent of patients discontinued therapy due to red eyes. Other common (approximately 20%) adverse reactions were: small deposits on the outer surface of the eye, mild pain upon instillation, and broken blood vessels on the white of the eye. Instillation site redness, corneal staining, blurred vision, increased tearing, redness of eyelid, and reduced visual acuity were reported in 5-10% of patients.

The small deposits on the outer surface of the eye seen in Rhopressa®-treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most small deposits on the outer surface of the eye resolved upon discontinuation of treatment.

Please see full Rhopressa® Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATION

Rhopressa® (netarsudil ophthalmic solution) 0.02% is a prescription medication for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening.

+

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Bacterial Keratitis: Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.

Contact Lenses: Contact lenses should be removed prior to using Rhopressa® and may be reinserted 15 minutes following its administration.

ADVERSE REACTIONS

The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was red eyes, in 53% of patients. Six percent of patients discontinued therapy due to red eyes. Other common (approximately 20%) adverse reactions were: small deposits on the cornea, mild pain upon instillation, and broken blood vessels on the white of the eye. Instillation site redness, corneal staining, blurred vision, increased tearing, redness of eyelid, and reduced visual acuity were reported in 5-10% of patients.

The small deposits on the outer surface of the eye seen in Rhopressa®-treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most small deposits on the outer surface of the eye resolved upon discontinuation of treatment.

Please see full Rhopressa® Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATION

Rhopressa® (netarsudil ophthalmic solution) 0.02% is a prescription medication for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening.